Synmosa Biopharma (4114) — Capital Reinvestment Ratio
Synmosa Biopharma (4114) has a Capital Reinvestment Ratio of 0.32x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$185.72 Million) in capital expenditures (NT$59.46 Million). Check 4114 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Synmosa Biopharma Capital Reinvestment Ratio (2015–2025)
This chart tracks Synmosa Biopharma's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see 4114 cash flow conversion.
Annual Capital Reinvestment Ratio for Synmosa Biopharma (2015–2025)
Year-by-year Capital Reinvestment Ratio for Synmosa Biopharma from 2015 to 2025. See 4114 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.68x | NT$411.57 Million | NT$281.13 Million | ▲ +97.7% |
| 2024 | 0.35x | NT$780.62 Million | NT$269.65 Million | ▼ -34.4% |
| 2023 | 0.53x | NT$511.93 Million | NT$269.77 Million | ▲ +156.9% |
| 2022 | 0.21x | NT$630.25 Million | NT$129.29 Million | ▼ -2.1% |
| 2021 | 0.21x | NT$444.29 Million | NT$93.06 Million | ▼ -65.5% |
| 2020 | 0.61x | NT$254.40 Million | NT$154.41 Million | ▼ -96.9% |
| 2018 | 19.66x | NT$16.00 Million | NT$314.43 Million | ▲ +996.6% |
| 2016 | 1.79x | NT$236.48 Million | NT$423.92 Million | ▼ -88.5% |
| 2015 | 15.65x | NT$23.60 Million | NT$369.26 Million | — |